Literature DB >> 11521081

CD14: a bridge between innate immunity and adaptive IgE responses.

D Vercelli1, M Baldini, D Stern, I C Lohman, M Halonen, F Martinez.   

Abstract

Total IgE levels are known to be under genetic control. Linkage studies have indicated that one or more loci on chromosome 5q may control total IgE, as well as asthma and bronchial hyperresponsiveness to non-specific stimuli. Our group has undertaken a systematic analysis of chromosome 5q, and has recently characterized five single nucleotide polymorphisms at position -1619, -1359, -1145, -809, and -159 in the promoter of the gene encoding CD14, the myeloid pattern recognition receptor that is critical for efficient innate immune responses to lipopolysaccharide and bacterial ligands. Individuals homozygous for the three major CD14 haplotypes found in the Children Respiratory Study population (n = 390) were analyzed for serum levels of total IgE and soluble CD14. A strong inverse correlation was found between these two parameters, i.e. carriers of the -1359T/-1145A/-159C haplotype had the highest levels of IgE, and the lowest levels of sCD14. Conversely, carriers of the -1359G/-1145G/-159T haplotype had the highest levels of sCD14 and the lowest IgE values. Our results suggest that genetic variation in CD14, a key gene of innate immunity, may modulate the effects that exposure to bacterial ligands has on the development of Th2 responses.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11521081

Source DB:  PubMed          Journal:  J Endotoxin Res        ISSN: 0968-0519


  20 in total

Review 1.  Innate immune responses to environmental allergens.

Authors:  Henk F Kauffman
Journal:  Clin Rev Allergy Immunol       Date:  2006-04       Impact factor: 8.667

2.  Association of CD14 gene -159C/T polymorphism with allergic rhinitis risk: a meta-analysis.

Authors:  Yu Xu; Jun Wang
Journal:  Eur Arch Otorhinolaryngol       Date:  2013-10-30       Impact factor: 2.503

3.  CD14 influences host immune responses and alternative activation of macrophages during Schistosoma mansoni infection.

Authors:  Smanla Tundup; Leena Srivastava; Tamas Nagy; Donald Harn
Journal:  Infect Immun       Date:  2014-05-27       Impact factor: 3.441

4.  Association study using combination analysis of SNP and STRP markers: CD14 promoter polymorphism and IgE level in Taiwanese asthma children.

Authors:  Jiu-Yao Wang; Ling-Mei Wang; Cherry Guan-Ju Lin; Ashely Ching-Wei Chang; Lawrence Shih-Hsin Wu
Journal:  J Hum Genet       Date:  2004-12-16       Impact factor: 3.172

5.  Polymorphisms of the CD14 gene and atopic phenotypes in Czech patients with IgE-mediated allergy.

Authors:  Dana Bučková; Lydie Izakovičová Hollá; Vladimír Znojil; Anna Vašků
Journal:  J Hum Genet       Date:  2006-09-27       Impact factor: 3.172

6.  The CD14 C-159T polymorphism is not associated with asthma or asthma severity in an Australian adult population.

Authors:  M-A Kedda; F Lose; D Duffy; E Bell; P J Thompson; J Upham
Journal:  Thorax       Date:  2005-03       Impact factor: 9.139

Review 7.  Soluble CD14: role in atopic disease and recurrent infections, including otitis media.

Authors:  Karin C Lødrup Carlsen; Berit Granum
Journal:  Curr Allergy Asthma Rep       Date:  2007-11       Impact factor: 4.806

8.  Innate immunity genes influence the severity of acute appendicitis.

Authors:  Fernando A Rivera-Chavez; Dixie L Peters-Hybki; Robert C Barber; Guy M Lindberg; Ishwarlal Jialal; Robert S Munford; Grant E O'Keefe
Journal:  Ann Surg       Date:  2004-08       Impact factor: 12.969

Review 9.  Toll-like receptors and immune response in allergic disease.

Authors:  Sophie C Gangloff; Moncef Guenounou
Journal:  Clin Rev Allergy Immunol       Date:  2004-04       Impact factor: 8.667

Review 10.  Gene Association with Leprosy: A Review of Published Data.

Authors:  Priscila Saamara Mazini; Hugo Vicentin Alves; Pâmela Guimarães Reis; Ana Paula Lopes; Ana Maria Sell; Manuel Santos-Rosa; Jeane Eliete Laguila Visentainer; Paulo Rodrigues-Santos
Journal:  Front Immunol       Date:  2016-01-12       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.